Fusion Pharmaceuticals (FUSN)
(Delayed Data from NSDQ)
$21.45 USD
-0.04 (-0.19%)
Updated May 3, 2024 04:00 PM ET
After-Market: $21.45 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
FUSN 21.45 -0.04(-0.19%)
Will FUSN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for FUSN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FUSN
Fusion Pharmaceuticals Inc. (FUSN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
FUSN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fusion Pharmaceuticals Inc. (FUSN) Ascends But Remains Behind Market: Some Facts to Note
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
Fusion Pharmaceuticals Inc. (FUSN) Stock Moves -0.09%: What You Should Know
Other News for FUSN
Radiopharma stocks higher as sector welcomes the latest M&A deal
Top 4 Health Care Stocks That May Plunge This Month
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Laboratory (LH), Fusion Pharmaceuticals (FUSN) and Integer Holdings (ITGR)
Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order
Fusion Pharmaceuticals management to meet with Oppenheimer